Vaccine-induced CD8+ T cells eliminate tumors by a two-staged attack

Cancer Gene Therapy

Volumn 10, Issue 12, 2003, Pages 870-878

  Kowalczyk, Dariusz W ^a,b   Wlazlo, Anthony P ^b   Giles Davis, Wynetta ^b   Kammer, Andreas R ^b,c   Mukhopadhyay, Sunil ^d   Ertl, Hildegund C J ^b  

^a Greatpoland Cancer Center   (Poland)

^b WISTAR INSTITUTE   (United States)

^c Pevion Biotech Ltd   (Switzerland)

^d Amersham Biosciences   (United States)

Author keywords

CD8+ T cells; HPV; Oncoproteins; Vaccines

Indexed keywords

ADHU5E7; CANCER VACCINE; CD8 ANTIGEN; GAMMA INTERFERON; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOLYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TARGET CELL DESTRUCTION; TUMOR CELL; TUMOR REJECTION;

ADENOVIRIDAE; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; HUMANS; INTERFERON TYPE II; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PORE FORMING CYTOTOXIC PROTEINS;

ANIMALIA;

EID: 0348014415     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700653     Document Type: Article

References (28)

1. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA. 1998;95:7556-7561.
2. Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol. 2001;13:114-119.
3. Wang RF, Rosenberg SA. Human tumor antigens for cancer vaccine development. Immunol Rev. 1999;170:85-100.
4. He Z, Wlazlo AP, Kowalczyk DW, et al. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology. 2000;270:146-161.
5. Rothstein TL, Mage M, Jones G, et al. Cytotoxic T lymphocyte sequential killing of immobilized allogeneic tumor target cells measured by time-lapse microcinematography. J Immunol. 1978;121:1652-1656.
6. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol. 2001;19:65-91.
7. Kowalczyk DW, Wlazlo AP, Blaszczyk-Thurin M, et al. A method that allows easy characterization of tumor-infiltrating lymphocytes. J Immunol Meth.. 2001;253:163-175.
8. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996;56:21-26.
9. Kleinman HK, McGarvey ML, Liotta LA, et al. Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. Biochemistry. 1982;21:6188-6193.
10. Passaniti A, Taylor RM, Pili R, et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest. 1992;67:519-528.
11. Vicari AP, Ait-Yahia S, Chemin K, et al. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol. 2000;165:1992-2000.
12. Romagnani P, Annunziato F, Lasagni L, et al. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest. 2001;107:53-63.
13. Salcedo R, Resau JH, Halverson D, et al. Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells. FASEB J. 2000;14:2055-2064.
14. Qin Z, Blankenstein T. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity. 2000;12:677-686.
15. Beatty G, Paterson Y. IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma. J Immunol. 2001;166:2276-2282.
16. Angiolillo AL, Sgadari CTosato G. A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann NY Acad Sci. 1996;795:158-167.
17. Weston SA, Parish CR. New fluorescent dyes for lymphocyte migration studies. Analysis by flow cytometry and fluorescence microscopy. J Immunol Med. 1990;133:87-97.
18. Gudmundsdottir H, Wells AD, Turka LA. Dynamics and requirements of T cell clonal expansion in vivo at the single-cell level: effector function is linked to proliferative capacity. J Immunol. 1999;162:5212-5223.
19. Seliger B, Killian M, Pfizenmaier K. Distinct mechanisms of interferon-gamma and tumor necrosis factor-alpha action in oncogene-transformed mouse fibroblasts. J Cell Chem. 1988;38:205-212.
20. Emilie D, Maillot MC, Nicolas JF, et al. Antagonistic effect of interferon-gamma on tat-induced transactivation of HIV long terminal repeat. J Biol Chem. 1992;267:20565-20570.
21. Freeman MR, Schneck FX, Gagnon ML, et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res. 1995;55:4140-4145.
22. Peoples GE, Blotnick S, Takahashi K, et al. T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: a potential pathologic role. Proc Natl Acad Sci USA. 1995;92:6547-6551.
23. Kotecha MT, Afghan RK, Vasilikopoulou E, et al. Enhanced tumour growth after DNA vaccination against human papilloma virus E7 oncoprotein: evidence for tumour-induced immune deviation. Vaccine. 2003;21:2506-2515.
24. Xiang ZQ, Yang Y, Wilson JM, et al. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology. 1996;219:220-227.
25. Kowalczyk DW, Wlazlo AP, Giles-Davis W, et al. Staining of antigen activated lymphocytes (SAAL): a highly specific method for flow cytometric quantitation of tumor-specific CD8(+) T cells. J Immunol Meth. 2000;241:131-139.
26. Blaszczyk-Thurin M, O I, Ertl HC. An experimental vaccine expressing wild-type p53 induces protective immunity against glioblastoma cells with high levels of endogenous p53. Scand J Immunol. 2002;56:361-375.
27. Vierboom MP, Feltkamp MC, Neisig A, et al. Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope. J Immunother. 1998;21:399-408.
28. Vierboom MP, Nijman HW, Offringa R, et al. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med. 1997;186:695-704.